Below are treatment recommendations from NHF's Medical and Scientific Advisory Council (MASAC). To learn more about MASAC, click here.
MASAC Document #216
MASAC Statement Regarding Inhibitor Risk of Factor VIII Concentrates
MASAC Document #212
MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia
MASAC Document #213
MASAC Recommendations for Treatment of Chronic HCV Infection in Individuals with Hemophilia and other Rare Bleeding Disorders
MASAC Document #214
MASAC Recommendations on the NHF Genotyping Project for Persons with Hemophilia
MASAC Document #215
MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders (Revised November 2012)
MASAC Document #211
MASAC Recommendations Regarding Inhibitor Risk and Recombinant Factor VIII Concentrates
MASAC Document #209
MASAC Statement on Biosimilars
MASAC Document #208
MASAC Recommendation on Orphan Drugs
MASAC Document #207
MASAC Recommendations Regarding Non-sterile Alcohol Prep Pads
MASAC Document #206
MASAC Recommendations Regarding Rare Coagulation Factor Disorders
MASAC Document #205
MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and other Bleeding Disorders
MASAC Document #204
MASAC Recommendations Regarding Physical Therapy Guidelines in Patients with Bleeding Disorders
MASAC Document #201
MASAC Recommendations on use of Emergency Medical Identification Devices for Children
MASAC Document #199
MASAC Resolution on Blood Donor Deferral Policy
MASAC Document #197
MASAC Recommendations Regarding Girls and Women with Inherited Bleeding Disorders
MASAC Document #196
MASAC Recommendations Regarding the Treatment of von Willebrand Disease
MASAC Document #194
MASAC Recommendations Regarding Radionuclide Synovectomy
MASAC Document #192
MASAC Guidelines for Perinatal Management of Women with Bleeding Disorders and Carriers of Hemophilia A and B
MASAC Document #191
MASAC Recommendation for Ongoing CDC Surveillance for CJD
MASAC Document #189
MASAC Consensus Statement on Plasma Safety
MASAC Document #188
MASAC Recommendations Regarding Standards of Service for Pharmacy Providers of Clotting Factor Concentrates for Home Use to Patients with Bleeding Disorders
MASAC Document #184
MASAC Concensus Statement Regarding the use of Fresh Frozen Plasma for the Immediate Reversal of the Anticoagualnt Effects and/or Bleeding Complications Associated with Oral Vitamin K Antagonists
MASAC Document #183
MASAC Statement Regarding use of Herbal or Homeopathic Products to Treat Von Willebrand Disease
MASAC Document #180
MASAC Endorsement of the NHLBI Consensus Guidelines on the Diagnosis and Treatment of von Willebrand Disease
MASAC Document #179
MASAC Recommendation Concerning Prophylaxis (Revised November 2007)
MASAC Document #175
Guidelines For Emergency Department Management Of Individuals With Hemophilia
MASAC Document #171
MASAC Resolution on National Hemophilia Foundation Sponsorship of Gene Therapy and Novel Technologies Workshops
MASAC Document #169
MASAC Recommendation Regarding the Use of Recombinant Clotting Factor Products with Respect to Pathogen Transmission
MASAC Document #168
MASAC Recommendation Regarding Access to Care For Patients with Bleeding Disorders
MASAC Document #167
MASAC Recommendation Regarding the Use of Bypassing Agents in Patients with Hemophilia A or B and Inhibitors
MASAC Document #166
MASAC Resolution Regarding Preferrred Drug Lists
MASAC Document #162
MASAC Recommendations on Use of Cox-2 Inhibitors in Persons with Bleeding Disorders
MASAC Document #161
MASAC Resolution on Stem Cell Research for Potential Cure of Bleeding Disorders
MASAC Document #160
MASAC Recommendation on the Need for Long-Term Follow-Up of Hemophilic Dogs in Gene Transfer Studies
MASAC Document #159
MASAC Recommendation Regarding Factor Concentrate Prescriptions and Formulary Development and Restrictions
MASAC Document #158
MASAC Recommendations Regarding Exposure to Blood Product Derivatives and Potential Risk of vCJD.
MASAC Document #157
MASAC Resolution on the Thrombogenicity of Bypassing Agents for Management of Hemophilia Complicated by Inhibitors
MASAC Document #154
MASAC Recommendations regarding the use of antiretroviral therapy in the treatment of HIV infection.
MASAC Document #153
MASAC Recommendation Concerning Reimbursement for Recombinant Clotting Factor Concentrates
MASAC Document #152
MASAC Recommendations Regarding the Inclusion of Thrombophilia in NHF Research and Educational Efforts
MASAC Document #150
MASAC Recommendations on the Use of Blood Products during Pregnancy and Testing for Parvovirus B19
MASAC Document #149
MASAC Recommendation on the World Health Organization Essential Drug List
MASAC Document #148
MASAC Resolution on NHF Educational Program for Fellows
MASAC Document #147
Transition Guidelines for People with Bleeding Disorders
View all MASAC Documents >>